110 likes | 141 Views
Pompe Disease market outlook helps in building the detailed comprehension of the historical, current and forecasted trend of the market by evaluating the impact of present therapies on the market, unmet needs, drivers and barriers and need of better technology. The expected launch of emerging therapies such as AT-GAA (Amicus Therapeutics), is assumed to create an affirmative impact on the Pompe Disease market in the upcoming years.
E N D
Pompe Disease Deficiency in GAA affects lysosomal-mediated degradation of glycogenesis and results in intralysosomal accumulation of glycogen. Three major forms of Pompe Disease are classic infantile-onset, non-classic variant of infantile-onset, and late-onset. Pompe Disease is classified on the basis of age of onset, organ involvement, severity, and the rate of disease progression. Pompe disease is an autosomal recessive inherited disorder caused by a mutation in the gene encoding GAA. 01 02 03 04 • DelveInsight © 2019 | All rights reserved
Pompe Disease Epidemiology Affected • Pompe disease prevalenceis estimated to be 1 in 40,000 with the disease affecting males and females equally. Prevalence Pompe disease prevalence is approximately 1 in 28,000 in the United States. Incidence • Pompe Disease Incidence is usually estimated to be 1:40,000 live births with the late-onset form of the disease Variation The disease has a variation between different ethnic groups like African Americans having an incidence as high as 1:14,000. • DelveInsight © 2019 | All rights reserved
Pompe Disease Market Outlook Pompe Disease Market size in the United States was estimated at USD 293 million in 2017. Expected launch of emerging therapies such as AT-GAA by Amicus Therapeutics, shall increase Pompe disease market size. United States represents a rapidly growing market space for Pompe Disease treatment during the study period [2017-2028]. 01 02 03 04 05 Extensive research and development activities by companies for developing the therapies along with the rising prevalent population, the Pompe disease market is expected to rise. Owing to the launch of upcoming therapies, the Pompe disease market size shall increase significantly during forecast period (2019-2028) • DelveInsight © 2019 | All rights reserved
Pompe Disease Emerging Drugs Drug: AT-GAA by Amicus Therapeutics There is a slew of pharmaceutical companies that are developing Pompe disease drugs like Amicus Therapeutics, Actus therapeutics and many others. Drug: ACTUS-101 by Actus Therapeutics • DelveInsight © 2019 | All rights reserved
Complete Information For complete information on Pompe Disease Market Insights, Epidemiology & Market Forecast-2028 please click the link below CLICK HERE OR Write Us At info@delveinsight.com • DelveInsight © 2019 | All rights reserved
About DelveInsight 2 1 3 Mission About To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. Vision DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. • DelveInsight © 2019 | All rights reserved
Service Offerings by DelveInsight PharmDelve Forecasting OpportunityAssessment Consulting ReportStore MarketIntelligence Competitive Analysis Pipeline • DelveInsight © 2019 | All rights reserved
Contact Us info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight • DelveInsight © 2019 | All rights reserved